Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by OmRx Oncology

OmRx Oncology Initiates Phase 2 Trial of Oral PD-L1 Inhibitor OX-4224 in NSCLC
From OmRx Oncology
Via Business Wire
OmRx Oncology Launches to Advance Investigational Oral Checkpoint Inhibitor Designed to Increase Access to Cancer Immunotherapy Worldwide
From OmRx Oncology
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.